S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
Log in

NASDAQ:PRVBProvention Bio Stock Price, Forecast & News

$11.87
-0.33 (-2.70 %)
(As of 07/14/2020 11:32 AM ET)
Add
Compare
Today's Range
$11.71
Now: $11.87
$12.46
50-Day Range
$12.19
MA: $14.29
$17.00
52-Week Range
$4.72
Now: $11.87
$18.50
Volume16,666 shs
Average Volume1.88 million shs
Market Capitalization$575.34 million
P/E RatioN/A
Dividend YieldN/A
Beta3.96
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRVB
CUSIPN/A
CIKN/A
Phone908-336-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-43,280,000.00

Miscellaneous

Employees13
Market Cap$575.34 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter.

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

How has Provention Bio's stock been impacted by COVID-19 (Coronavirus)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRVB shares have increased by 31.6% and is now trading at $11.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Provention Bio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Provention Bio.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Provention Bio.

How were Provention Bio's earnings last quarter?

Provention Bio Inc (NASDAQ:PRVB) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.01. View Provention Bio's earnings history.

What price target have analysts set for PRVB?

6 Wall Street analysts have issued 1 year target prices for Provention Bio's shares. Their forecasts range from $25.00 to $40.00. On average, they anticipate Provention Bio's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 153.0% from the stock's current price. View analysts' price targets for Provention Bio.

Has Provention Bio been receiving favorable news coverage?

News headlines about PRVB stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Provention Bio earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Provention Bio.

Who are some of Provention Bio's key competitors?

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Myovant Sciences (MYOV), VBI Vaccines (VBIV), NVIDIA (NVDA), Opko Health (OPK), Vaxart (VXRT) and Clovis Oncology (CLVS).

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:
  • Mr. Ashleigh Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 56)
  • Mr. Francisco Leon M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 47)
  • Mr. Andrew T. Drechsler, Chief Financial Officer (Age 47)
  • Dr. Eleanor L. Ramos, Chief Medical Officer & COO (Age 63)
  • Mr. Cameron Gray Ph.D., MD & Director (Age 46)

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $11.86.

How big of a company is Provention Bio?

Provention Bio has a market capitalization of $574.85 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 13 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.